In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 54 for your search:
Drug:  idarubicin
Find trials that include:  Any drugs shown
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase IV
Type: Treatment
Status: Active
Age: Over 55
Sponsor: Other
Protocol IDs: GMALL02, NCT00198978

2.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 65
Sponsor: Other
Protocol IDs: GMALL01, NCT00198991

3.

Phase: Phase IV
Type: Treatment
Status: Active
Age: Over 60
Sponsor: Other
Protocol IDs: AML-elderly 01/99 Trial, NCT00199147

4.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: MK1-192, NCT00180128

5.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 0 to 75
Sponsor: Other
Protocol IDs: LPA 2005, NCT00408278

6.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 55 and over
Sponsor: Other
Protocol IDs: LAL-07OLD, NCT01366898

7.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 60
Sponsor: Other
Protocol IDs: LAL-AR/2011, NCT01540812

8.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 to 65
Sponsor: Other
Protocol IDs: HIE-ALL-2013, NCT01873807

9.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: APL2012, NCT01987297

10.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 6 months to 18 years
Sponsor: Other
Protocol IDs: CCALL2012, NCT01990807

11.

Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: MYFLAI07, NCT00909168

12.

Phase: Phase III
Type: Treatment
Status: Active
Age: 16 to 65
Sponsor: Other
Protocol IDs: NILG-AML 02/06, NCT00495287

13.

Phase: Phase III
Type: Treatment
Status: Active
Age: 6 months to 21 years
Sponsor: Other
Protocol IDs: CWS-2007-HR, 4033024 (BfArM), 293/2007AMG1 (Ethikkommission), 2007-001478-10, A2007/14 (Kinderkrebsstiftung), 498 (Krebsstudienregister), NCT00876031

14.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AMLSG 09-09, NCT00893399

15.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: C-022, NCT01145846

16.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: AML 2002 #061, NCT01414231

17.

Phase: Phase III
Type: Treatment
Status: Active
Age: 7 to 60
Sponsor: Other
Protocol IDs: MST-AML-307PLAH-ASH, NCT01484171

18.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 50
Sponsor: Other
Protocol IDs: GuangXi-AML- HSCT-2012-07, NCT01766375

19.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 15 to 60
Sponsor: NCI
Protocol IDs: NCI-2013-00490, SWOG-S1203, S1203, U10CA032102, NCT01802333

20.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: EORTC-06061, EU-20905, 2006-004912-28, GIMEMA-AML-14A, EudraCT-2006-004912-28, NCT00838240

21.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MCC-15625, RV-AML/MDS-PI-0269, NCT00831766

22.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2010-0788, NCI-2011-00251, NCT01289457

23.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: PLERIFLAG, NCT01435343

24.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 20 to 65
Sponsor: Other
Protocol IDs: AML-2011-01, NCT01518556

25.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: KS-2009-003, 2010-021719-18, NCT01534702
1    
New Search